Laufer L R, Erlik Y, Meldrum D R, Judd H L
Obstet Gynecol. 1982 Nov;60(5):583-6.
The effectiveness of clonidine in suppressing the occurrence of postmenopausal hot flashes was examined using a dose-response study design and objective recordings of hot flashes. Patients with frequent flashes were studied before and after oral administration of placebo and 0.1, 0.2, and 0.4 mg of clonidine daily for 2 weeks at each dose level. Finger temperature and skin resistance were recorded as indices of hot flash episodes. Four of 10 subjects beginning the study withdrew because of drug-related side effects. Clonidine was found to reduce significantly the frequency of hot flashes as compared with baseline (P less than .005) and with effects of the placebo (P less than .05). At the maximum dosage the mean rate of hot flash occurrence decreased 46%. It was concluded that clonidine does reduce the frequency of postmenopausal flashes.
采用剂量反应研究设计和潮热客观记录方法,研究可乐定抑制绝经后潮热发生的有效性。对潮热频繁的患者在口服安慰剂以及每日分别服用0.1毫克、0.2毫克和0.4毫克可乐定,每种剂量水平服用2周前后进行研究。记录手指温度和皮肤电阻作为潮热发作的指标。开始研究的10名受试者中有4人因药物相关副作用退出。结果发现,与基线相比(P<0.005)以及与安慰剂的效果相比(P<0.05),可乐定能显著降低潮热频率。在最大剂量时,潮热发生的平均速率降低了46%。得出的结论是,可乐定确实能降低绝经后潮热的频率。